We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.
The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.
Several pharmaceutical and biotechnology companies in China are actively involved in the research and development of Central Nervous System (CNS) drugs.
AdvertisingEmail to: Julia.zhang@imsinoexpo.com
Media CooperationEmail to: Jennifer.Yang@imsinoexpo.com
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!